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Objectives. Measurement of QT interval dispersion during
pharmacologic adrenergic stimulation was used to assess the
effect of alpha- and beta-adrenergic stimulation on arrhythmic
vulnerability in familial long QT syndrome (LQTS).
Background. Nonhomogeneity in the ventricular action poten-
tial duration causes electrical instability leading to life-
threatening ventricular arrhythmias and is markedly increased in
LQTS. QT interval dispersion measured from the electrocardio-
gram (ECG) can be used as an index of nonhomogeneous ventric-
ular repolarization.
Methods. Sixteen symptomatic patients with LQTS and nine
healthy control subjects were examined at baseline and during
epinephrine (mainly beta-adrenergic agonist, 0.05 mg/kg body
weight per min) and phenylephrine infusions (alpha-adrenergic
agonist, mean 1.4 mg/kg per min). QT interval dispersion was
determined from a 12-lead ECG as interlead range and coefficient
of variation measured to the end (QTend) and apex (QTapex) of the
T wave.
Results. At baseline QTend dispersion was greater in patients
with LQTS compared with control subjects (mean [6SD] 68 6 34
vs. 36 6 7 ms, p 5 0.001). QTend dispersion was markedly
increased in patients with LQTS by use of epinephrine (from 68 6
34 to 90 6 36 ms, p 5 0.002), but remained unchanged in control
subjects. Phenylephrine did not affect QT dispersion in either
group (all p 5 NS). Atrial pacing to achieve comparable heart
rates during baseline and epinephrine and phenylephrine infu-
sions did not influence the magnitude of QT dispersion in either
group. QTapex dispersion analysis gave congruent results.
Conclusions. Epinephrine but not phenylephrine increased QT
dispersion, suggesting that beta-adrenergic stimulation provokes
arrhythmias in patients with LQTS by aggravating nonhomoge-
neity of ventricular repolarization, whereas alpha-adrenergic
stimulation is less important for arrhythmic vulnerability. The
results also suggest that rapid pacing may not reduce vulnerabil-
ity to arrhythmias in congenital LQTS.
(J Am Coll Cardiol 1998;31:1400–5)
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Nonuniform recovery of excitability is an important underlying
mechanism of malignant ventricular arrhythmias (1–4). Famil-
ial long QT syndrome (LQTS) is a clinical disorder character-
ized by abnormal ventricular repolarization, ventricular ar-
rhythmias triggered by sympathetic nervous activation and
sudden death (5,6). Standard electrocardiography is a clinically
available method to examine heterogeneity of ventricular
repolarization, and interlead variability of the QT inter-
val—QT dispersion—has been proposed as a marker of elec-
trical instability of the heart (7,8). The shape and width of the
T wave reflect local differences in recovery of excitability (9), a
factor known to increase a patient’s propensity to develop
ventricular fibrillation. QT dispersion is markedly increased in
patients with LQTS, which has been considered to indicate
arrhythmia risk (8) in this disease. It has also been proposed
that QT dispersion can predict therapeutic efficacy in LQTS,
although its discriminating power may be insufficient to be a
useful clinical tool (10,11).
Sympathetic nervous stimulation and catecholamines are
known to produce QT prolongation and ventricular arrhyth-
mias in familial LQTS (5,12). In the present study we examined
the influence of alpha- and beta-adrenergic stimulation of QT
dispersion in LQTS. Phenylephrine was used to produce
alpha-adrenergic stimulation and epinephrine mainly beta-
adrenergic stimulation. Because these pharmacologic interven-
tions alter heart rate considerably, cardiac cycle length was
controlled by atrial pacing. Also, the QT interval and ventric-
ular monophasic action potential duration (MAPd) were ex-
amined.
Methods
Study subjects. Sixteen patients (12 women and 4 men, age
range 6 to 66 years) with congenital LQTS were included in the
study. All of these patients had a history of syncope, family
members with diagnosed LQTS and a corrected QT interval
(QTc) .440 ms (range 450 to 700). Nine other patients
participating in a control electrophysiologic study after previ-
ous catheter ablation served as control subjects (4 women and
5 men, age range 19 to 59 years), and all had a structurally
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normal heart and a normal QTc (,440 ms). All patients with
LQTS and control subjects were examined without any antiar-
rhythmic medication, including beta-adrenergic antagonists.
The study was approved by the Institutional Ethical Review
Board, and each patient gave written informed consent.
Test procedure. Three quadripolar electrical catheters
were placed in the right atrium, atrioventricular junction and
right ventricle. MAP was recorded from the right ventricular
septum using a silver/silver chloride MAP catheter and a 0.05-
to 250-Hz bandpass filter. Blood pressure was measured from
a femoral artery cannula. Standard 12-lead ECG, MAP and
arterial pressure were recorded and stored digitally at a sample
rate of 1 kHz (Cardiolab, Prucka Engineering).
The study data were obtained at baseline and under stabi-
lized conditions during epinephrine and phenylephrine infu-
sions. The target rate of epinephrine infusion was 0.05 mg/kg
per min, which was reached stepwise while provocation of
arrhythmias was carefully monitored. A phenylephrine dose of
1 to 2 mg/kg per min (average 1.4 mg/kg per min) was chosen
to increase systolic arterial pressure by 30 mm Hg. Two
patients with LQTS and two control subjects did not receive
phenylephrine owing to high baseline arterial pressure or
discomfort during the preceding epinephrine phase. None of
the patients had frequent premature ventricular beats to
prevent the analysis or any ventricular tachycardia during the
test infusions.
Recordings were performed during sinus rhythm, and atrial
pacing was maintained at least 30 s before measurement. The
targeted pacing cycle intervals were 700, 600 and 500 ms. Data
were not obtained at all cycle intervals because of a faster sinus
rate or decreased atrioventricular node conductivity during
pharmacologic interventions.
Measurements. QT and sinus cycle lengths (RR intervals)
were measured from a computer display with 0.05 mV/mm
amplification and 100 mm/s sweep speed using cursor-moved
calipers with a discrimination accuracy of 1 ms (Cardiolab,
Prucka Engineering). Omitted were leads with near isoelectric
T waves and recordings where the paced atrial signal was
superimposed on the peak or end of the T wave. To compen-
sate for missing data at the 600-ms cycle interval, values from
the 700-ms or 500-ms cycle interval were used in zero to two
cases per group during drug infusions for analysis of QT
dispersion (but not of QT interval duration).
The QT interval was measured from the onset of the QRS
deflection to end of the T wave (QTend), defined as the
intersection of the isoelectric baseline and the tangent of the
maximal downward T wave slope. The QT apex interval
(QTapex) was measured to the T wave apex, defined as the
maximal amplitude of the dominant T wave component,
whether positive or negative. The ventricular MAPd was
determined at 90% of repolarization using cursor-moved cal-
ipers. The intervals and arterial pressure were determined
from the same heart beats. All measurements were performed
by one of the investigators.
Data were accepted for dispersion analysis if at least nine
ECG leads were analyzable. QT dispersion was examined
using two indexes: interlead range as the longest minus short-
est QT interval in any ECG lead and coefficient of variation of
QT intervals. The latter index was obtained by dividing the
standard deviation by the mean of the QT intervals, expressed
as a percentage. This index attempted to avoid biases inherent
in using two extreme values only and having groups with
dissimilar QT interval durations. Dispersion was calculated for
QTend and QTapex data. The QTend interval was corrected to
heart rate (QTc) by using Bazett’s formula: QTc 5 QT/=RR.
The given QTend, QTapex and QTc interval durations are
means of all measured leads. Figure 1 illustrates the measure-
ment of QTend dispersion in a patient with LQTS.
Statistical analysis. Continuous variables are expressed as
the mean value 6 SD. Differences between patients with
LQTS and control subjects were assessed using analysis of
variance and the t test. The effects of the pharmacologic tests
Abbreviations and Acronyms
ECG 5 electrocardiogram
LQTS 5 long QT syndrome
MAPd 5 monophasic action potential duration
QTapex 5 dispersion of QT apex intervals
QTc 5 corrected QT interval
QTend 5 dispersion of QT end intervals
Figure 1. Measurement of QTend interval dispersion of a 12-lead ECG
(limb, auxiliary and chest leads in standard order) of a patient with
LQTS. Vertical lines indicate earliest and latest T wave end in any lead
at baseline (left panel) and during infusion of epinephrine (right
panel).
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and atrial pacing were assessed by repeated measures analysis
of variance. Relations were examined using least squares linear
regression analysis. The chi-square test was used to examine
incidences in the groups. A p value ,0.05 was taken as
statistically significant.
Results
The LQTS and control groups did not differ with regard to
age, sinus cycle length or blood pressure. As anticipated by the
patient selection, the QT and QTc intervals and MAPd were
markedly longer in patients with LQTS than in control subjects
(Table 1).
QT dispersion in baseline. QTend dispersion was greater in
patients with LQTS than in control subjects (Table 2). QTapex
dispersion tended to be greater in patients with LQTS than in
control subjects during sinus rhythm and was clearly so during
atrial pacing.
QTend dispersion correlated with the QTend interval (r 5
0.66, p 5 0.001) and MAPd (r 5 0.65, p 5 0.001), but not with
the sinus cycle length in the LQTS group (r 5 0.04, p 5 NS).
Physiologic effects of adrenergic interventions. Epineph-
rine shortened sinus cycle length equally in both groups (Table
3). Epinephrine did not change the QTend interval in sinus
rhythm, but increased the QTc and paced QTend interval in the
LQTS group. In the control group epinephrine had no effect
on the QTend interval during pacing (Table 3). No statistically
significant effect on MAPd could be demonstrated during sinus
rhythm or pacing in either group.
Phenylephrine increased the sinus cycle length equally in
both groups (Table 3). Phenylephrine increased the QTend
interval in both groups but had no effect on the QTc or paced
QTend interval. Phenylephrine did not change MAPd during
atrial pacing in either group.
Systolic blood pressure was not influenced by epinephrine,
but phenylephrine increased it from 143 6 29 to 167 6
16 mm Hg (p 5 0.001) in the LQTS group and from 139 6 18
to 159 6 12 mm Hg (p 5 0.001) in the control group. The
changes were comparable in both groups (p 5 NS).
Adrenergic effects on QT dispersion. Epinephrine in-
creased QT dispersion markedly in the LQTS group (Fig. 2,
Table 4). The effects on QTend and QTapex dispersions were
comparable and both indexes—interval range and coefficient
of variation—showed similar results (Fig. 3). No respective
changes occurred in the control group (Table 4).
QTend and QTapex dispersions were not influenced by
phenylephrine in either group, with neither of the indexes
showing any statistically significant change (Table 4).
Pacing effect on QT dispersion. There were no statistically
significant differences in QT dispersion between sinus rhythm
and atrial pacing in either group at baseline (all comparisons
p 5 NS) (Table 2). Atrial pacing did not attenuate the
epinephrine-induced increase in QT dispersion in the LQTS
group (Table 5, Fig. 4), nor did pacing have any effect on QT
dispersion during phenylephrine.
Discussion
The present study of the effects of adrenergic stimulation
on ventricular repolarization in patients with LQTS showed
that epinephrine, mainly a beta-adrenergic agonist, increased
QT interval dispersion markedly, whereas phenylephrine, an
alpha-adrenergic agonist, had no influence on dispersion.
Epinephrine prolonged the QT interval in LQTS at a con-
trolled heart rate but did not influence MAPd in the right
ventricle, suggesting that local and overall ventricular repolar-
ization times became disparate.
Arrhythmias and autonomic nervous system in LQTS. The
basic abnormality in congenital LQTS is a mutation in the
genes coding a potassium channel in types 1 and 2 and a
sodium channel in type 3 of the syndrome (13–15). Physical
exertion and strong emotions are known to precipitate arrhyth-
mic syncope and sudden death in LQTS (5). Exercise testing
and isoproterenol infusion are reported to produce prolonga-
tion of the QT interval in LQTS (12,16). Protection against
sudden death by use of beta-adrenergic antagonists (6) and left
upper thoracic sympathectomy (17) confirms the importance
of sympathetic stimulation as a trigger of arrhythmias. Thus,
catecholamines play an important role in arrhythmogenesis in
Table 2. QT Dispersion in Patients With Long QT Syndrome and
Control Subjects at Baseline
Dispersion Index*
Patients With
LQTS
Control
Subjects
p
Value
During sinus rhythm n 5 16 n 5 9
QTend (ms) 68 6 34 36 6 7 0.002
QTend coeff (%) 4.2 6 1.8 2.8 6 0.6 0.010
QTapex (ms) 62 6 47 42 6 11 NS
QTapex coeff (%) 5.0 6 3.8 4.2 6 1.0 NS
During atrial pacing† n 5 14 n 5 9
QTend (ms) 61 6 32 37 6 11 0.023
QTend coeff (%) 4.1 6 1.8 3.2 6 1.2 0.050
QTapex (ms) 69 6 37 34 6 13 0.012
QTapex coeff (%) 7.0 6 4.4 3.6 6 1.5 0.033
*See Methods for explanation. †Atrial pacing was performed at a cycle
length of 600 ms. Data presented are mean value 6 SD. coeff 5 coefficient; other
abbreviations as in Table 1.
Table 1. Characteristics of the Study Groups
Patients With LQTS
(n 5 16)
Control Subjects
(n 5 9)
p
Value
Age (yr) 32 6 21 43 6 11 NS
SBP (mm Hg) 143 6 29 139 6 18 NS
Sinus cycle interval (ms) 875 6 203 859 6 216 NS
QTend interval (ms) 493 6 74 381 6 27 0.001
QTapex interval (ms) 376 6 41 300 6 29 0.001
QTc interval (ms) 531 6 52 417 6 31 0.001
MAPd (ms) 400 6 59 303 6 19 0.001
Data presented are mean value 6 SD. LQTS 5 long QT syndrome; MAPd
5 monophasic action potential duration; QTapex 5 dispersion of QT apex
intervals; QTc 5 corrected QT interval; QTend 5 dispersion of QT end intervals;
SBP 5 systolic blood pressure.
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LQTS and could act by exaggerating the preexisting repolar-
ization abnormalities.
Epinephrine stimulates myocardium mainly through beta1
receptors and less through beta2 receptors, whereas it induces
only mild myocardial alpha1 stimulation (18). The beta-
adrenergic receptor stimulation shortens and the alpha-
adrenergic receptor stimulation prolongs the action potential
duration in experimental preparations (19–21). The beta-
adrenergic stimulation produced in the present study was
modest because the heart rate was only slightly increased.
Catecholamines and QT dispersion. QT dispersion is in-
creased in familial LQTS (8,10,11). A sympathetic imbalance
hypothesis (22) has been previously promoted in LQTS but has
lost importance since the detection of ion channel defects as
the basic anomaly. A normal distribution and density of cardiac
sympathetic nerve terminals have been observed in LQTS (23),
suggesting a more complex genesis of QT dispersion than mere
differences in regional innervation.
In the present study, epinephrine increased QT dispersion
markedly in patients with congenital LQTS. Thus, increasing
the nonhomogeneity in ventricular repolarization is a possible
mechanism by which the beta-adrenergic agonists provoke
arrhythmias in LQTS. In addition, epinephrine prolonged the
QT interval at a controlled heart rate. This should be consid-
ered arrhythmogenic because a greater length of the QT
interval is associated with more malignant arrhythmias in
LQTS (24). The present results cannot answer whether the
increase in the dispersion or the duration of the QT interval is
more important for arrhythmogenesis. Because QT dispersion
was increased only by epinephrine and not by phenylephrine,
this action is attributed to the beta-adrenergic component of
the sympathetic system.
A recent report by Hirao et al. (25) showed that epineph-
rine increases the difference in ventricular MAPd recorded
from multiple intracardiac sites in patients with LQTS. Our
results are consistent with their findings, assuming that QT
dispersion on the surface ECG represents local differences in
repolarization time, as has been suggested (9). In our study, at
a controlled rate, epinephrine prolonged the QT interval
duration but did not influence ventricular MAPd, which might
represent different local responses (i.e., dispersion in ventric-
ular repolarization) during beta-adrenergic stimulation.
An important observation was that phenylephrine did not
increase QT dispersion in patients with LQTS. This suggests
that alpha-adrenergic stimulation does not increase nonunifor-
mity in ventricular repolarization, and because neither the QT
interval nor MAPd was prolonged at a controlled heart rate,
alpha-adrenergic stimulation would not be considered strongly
arrhythmogenic. Vagal stimulation prolongs ventricular action
potential duration largely by antagonizing the effect of beta-
adrenergic stimulation (26). Acetylcholine has dissimilar ef-
fects on ventricular endocardium and epicardium (27), and
thus could affect QT dispersion, although it is unknown
Figure 2. Dispersion of the QTend interval at baseline and during
infusion of epinephrine. Individual responses to epinephrine are
indicated during sinus rhythm and atrial pacing.
Table 3. Effect of Pharmacologic Adrenergic Stimulation on Duration of Ventricular Repolarization
During Sinus Rhythm and Atrial Pacing
Baseline Epinephrine p Value* Phenylephrine p Value*
Patients with LQTS n 5 16 n 5 16 n 5 14
Sinus cycle interval (ms) 875 6 203 702 6 104 0.001 992 6 242 0.017
QTend interval (ms) 493 6 74 490 6 70 NS 520 6 78 0.001
QTc interval (ms) 531 6 52 586 6 68 0.001 527 6 55 NS
MAPd (ms) 400 6 59 378 6 48 NS 414 6 53 0.048
Atrial pacing n 5 14 n 5 14 n 5 13
QTend interval (ms) 427 6 44 458 6 49 0.013 445 6 52 NS
MAPd (ms) 357 6 40 359 6 43 NS 348 6 33 NS
Control subjects n 5 9 n 5 9 n 5 7
Sinus cycle interval (ms) 859 6 216 697 6 172 0.005 957 6 215 0.002
QTend interval (ms) 381 6 27 370 6 30 NS 396 6 32 0.005
QTc interval (ms) 417 6 31 448 6 25 0.004 409 6 18 NS
MAPd (ms) 303 6 19 300 6 31 NS 326 6 30 NS
Atrial pacing n 5 9 n 5 8 n 5 5
QTend interval (ms) 364 6 31 365 6 18 NS 358 6 16 NS
MAPd (ms) 280 6 10 290 6 15 NS 291 6 21 NS
*Statistical significance refers to comparison with baseline value. Data presented are mean value 6 SD. Abbrevia-
tions as in Table 1.
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whether vagal stimulation does so in humans. Therefore,
baroreflex-mediated vagal stimulation during increased arte-
rial pressure might have obscured a possible direct effect of
phenylephrine on QT dispersion.
Effects of rate on QT dispersion. The noted absence of the
effect of cardiac pacing on QT dispersion indicates that the
opposite effects of alpha- and beta-adrenergic stimulations on
heart rate cannot explain the results. It also suggests that
pacing faster than the physiologic heart rate would not dimin-
ish QT dispersion in patients with LQTS in general. The
experience on clinical benefit of pacing in LQTS is at variance.
Some reports suggest that permanent pacing can reduce
recurrent syncopal events in high risk patients with LQTS (28)
and in patients with LQTS with conduction abnormalities (24).
Our results favor the view that the benefit of cardiac pacing is
due to prevention of severe bradycardia and cardiac pauses.
An exception is probably type 3 LQTS with a sodium channel
defect, where elevating the slow rest heart rate by pacing is
considered protective (29). Thus, our conclusions would not be
readily applicable to all LQTS subtypes.
Study limitations. Because of different individual physiol-
ogy, comparison during pharmacologic stimulation could not
always be performed at similar pacing cycle lengths. As noted
in the present and previous studies (10), QT dispersion is not
obviously dependent on heart rate, and therefore minor dif-
ferences in compared cycle lengths would not have confounded
the observations on QT dispersion.
Although care was taken to use consistent criteria to define
the end of the T wave and to exclude U waves, the latter may
have been unidentifiable across the leads and included in the
QT interval when prominent. The uncertainty in defining the
measurement points, owing to low T wave amplitude and
overlapping atrial signal, resulted in omitting some leads. This
would not diminish the comparability of our results, because
the practice is common in QT dispersion studies.
The genotype was not known in all patients, but according
to our previous analysis (30) of subtype distributions in the
geographic area, the majority of the patients likely had a
potassium channel abnormality of LQTS types 1 and 2. It is
possible that a difference in genotype may affect the individual
responses.
Conclusions. Modest beta-adrenergic stimulation in-
creases QT dispersion markedly, suggesting that this compo-
nent, as opposed to alpha-adrenergic stimulation, is most
important for arrhythmic vulnerability in congenital LQTS.
The results also suggest that pacing faster than the normal
Figure 3. Effect of epinephrine and phenylephrine on QT dispersion
during sinus rhythm in patients with LQTS. Solid columns represent
QTend and crosshatched columns QTapex dispersions (mean 6 SEM).
**p , 0.01 compared with baseline.
Table 5. Effect of Pacing on QT Dispersion in Patients With Long
QT Syndrome*
Dispersion
Index†
Sinus
Rhythm‡
Atrial
Pacing§
Baseline n 5 16 n 5 14
QTend (ms) 68 6 34 61 6 32
QTend coeff (%) 4.3 6 1.8 4.1 6 1.8
QTapex (ms) 61 6 46 64 6 26
Epinephrine n 5 16 n 5 14
QTend (ms) 90 6 36 86 6 31
QTend coeff (%) 5.8 6 2.0 5.4 6 1.5
QTapex (ms) 102 6 61 98 6 43
Phenylephrine n 5 14 n 5 13
QTend (ms) 71 6 37 67 6 31
QTend coeff (%) 3.8 6 1.5 4.6 6 2.0
QTapex (ms) 70 6 41 57 6 25
*p 5 NS for all comparisons. †See Methods for explanation. ‡Sinus cycle
intervals are given in Table 3. §Atrial pacing cycle interval was 600 ms. Data
presented are mean value 6 SD. Abbreviations as in Tables 1 and 2.
Table 4. Effect of Pharmacologic Adrenergic Stimulation on QT Dispersion
Dispersion Index* Baseline Epinephrine p Value† Phenylephrine p Value†
Patients with LQTS n 5 16 n 5 16 n 5 14
QTend (ms) 68 6 34 90 6 36 0.003 71 6 37 NS
QTend coeff (%) 4.3 6 1.8 5.8 6 2.0 0.002 3.8 6 1.5 NS
QTapex (ms) 62 6 47 102 6 61 0.006 70 6 47 NS
QTapex coeff (%) 5.0 6 3.8 9.7 6 6 0.008 5.1 6 3.3 NS
Control subjects n 5 9 n 5 9 n 5 9
QTend (ms) 36 6 7 38 6 13 NS 44 6 16 NS
QTend coeff (%) 2.8 6 0.6 3.1 6 1.2 NS 3.1 6 1.1 NS
QTapex (ms) 42 6 11 40 6 15 NS 39 6 14 NS
QTapex coeff (%) 4.2 6 1.0 4.5 6 1.9 NS 3.3 6 0.9 NS
*See Methods for explanation. †Statistical significance refers to comparison with baseline value. Data, presented as
mean value 6 SD, were obtained in sinus rhythm at intervals indicated in Table 3. Abbreviations as in Tables 1 and 2.
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heart rate may not reduce the vulnerability of these patients to
life-threatening arrhythmias.
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